Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aventis Defense Against Sanofi Begins With Genasense; Ketek, Exubera Also Overlooked, Firm Says

This article was originally published in The Pink Sheet Daily

Executive Summary

All three brands have blockbuster potential, Aventis says. The company predicts growth of 7%-8% in 2004 revenues, but says divestments of older brands may help enhance margins.

You may also be interested in...

Aventis Submits Taxotere sNDA In Early-Stage Breast Cancer; Two More Planned By Early 2005

The filing is the second of four supplements planned for the oncologic over the next year. A prostate cancer sNDA was submitted earlier in the year; filings for gastric cancer and head and neck cancer are expected.

Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues

“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts